CURRICULUM VITAE – FRANCISCO AUGUSTO SYLVESTER, M.D. Education Medical SchoolDegree: MD. Institution: Universidad Peruana Cayetano Heredia, Lima, Perú. Dates:4/1/1977 to 8/7/1985. Specialty: Physician and Surgeon Postgraduate TrainingDegree: None. Institution: Children's Medical Center of Brooklyn, New York (SUNYHealth Science Center at Brooklyn, Kings County Hospital). Residency: 7/1/1987 to6/30/1990. Chief Resident of Pediatrics from 7/1/1990 to 6/30/1991. Specialty:Pediatrics Degree: None. Institution: The Hospital for Sick Children (University of Toronto),Toronto, Canada. Clinical Fellow: July 1991 to June 1992; Research Fellow: July 1992to August 1995. Specialty: Pediatric gastroenterology Professional Experience – Employment History Academic Appointments at the University of North Carolina 10/2015 – Present: Professor of Pediatrics with tenure10/2014 – 10/2015: Nominated Clinical Professor of Pediatrics 10/2014 – Present: Division Chief, Pediatric Gastroenterology Academic Appointments at the University of Connecticut School of MedicinePlease note: As an employee of Connecticut Children’s Medical Center, an affiliatedinstitution to the University of Connecticut School of Medicine, I was not eligible fortenure or tenure track

• 9/2011 – 10/2014: Professor of Pediatrics and Immunology

• Cross appointment, Department of Immunology 4/1/2010 (Associate Professor)

• 9/2003 – 9/2011: Associate Professor of Pediatrics.

• 2/1996 – 9/2003: Assistant Professor of Pediatrics.

Other Professional Experience

• 07/2015 – present: Medical Director of Outpatient Clinics, North Carolina Children’sHospital

• 01/2013 – 03/31/2016: Chair, CCFA Pediatric Network (PROKIIDS)

• 7/1990 to 6/1991: Instructor of Pediatrics: SUNY Health Science Center atBrooklyn, Kings County Hospital, Brooklyn, New York

• 7/1987 to 6/1990: Clinical Assistant Instructor of Pediatrics: SUNY Health ScienceCenter at Brooklyn, Kings County Hospital, Brooklyn, New York.

• 9/1985 to 3/1986: Obligatory service for the Department of Health, Perú: Ciudad deDios Health Center, Lima, Perú. Primary care physician, taking care of patients in

Dios Health Center, Lima, Perú. Primary care physician, taking care of patients ina shantytown in Lima.

• 2/1986 to 4/1987: Nutrition Research Institute (Instituto de InvestigaciónNutricional): La Molina, Lima, Perú. Duties included care of malnourishedpatients (ambulatory and hospitalized children). Also participated in manyresearch projects (clinical and epidemiologic research) that were conducted inthis private and non-profit institution by American, British and Peruvianinvestigators.

Medical Licenses USA: North Carolina. Status: Active

Connecticut. Status: InactivePennsylvania License Status: Inactive

Perú: Colegio Médico del Perú (Peruvian College of Physicians). Status: Active Canada: Educational License (The College of Physicians and Surgeons ofOntario) Status: Expired after training period was completed in 8/1995 Consulting Clinical Advisory Board (CAB) of Landos Pharmaceuticals May 30, 2017 - present Honors

• Best Doctors in America® List 2017 - 2018

• Inaugural “Physician of Distinction” Award from the Connecticut Children’s MedicalCenter Medical Staff, 2009 (recognition for outstanding medical care, teachingand research)

• McNeill Teaching Award for excellence in resident teaching, University ofConnecticut Pediatric Residency Program, October 31, 2008 and February 12th,2009

• Didactic Teaching Award, University of Connecticut Pediatric Residency Program,February 13, 2009

• Faculty Award for Excellence in Teaching, University of Connecticut Pediatric

Residency Program, June 20, 2009• “Best Doctors” for the Greater Hartford area (selected by Best Doctors, Inc.):

Yearly since 2007 – 2014• Donaghue Investigator Award, Hartford, CT, January 2004

• Attending Spot Award For Excellence in Resident Teaching. University ofConnecticut School of Medicine, October 2002

• Faculty Award for Outstanding Teacher. University of Connecticut School ofMedicine, June 1997.

• Winner, Consults in Gastroenterology: A Case Study Competition for Fellows andResidents in Gastroenterology. The Canadian Association of Gastroenterology,January 1995. Paper: A rare form of chronic granulomatous disease presentingas inflammatory bowel disease.

• Research Institute, The Hospital for Sick Children (RESTRACOM) FellowshipAward: July 1, 1993 to July 30, 1995.

• Winner of the 1994 Tisdall Award Competition, The Hospital for Sick Children,

• Winner of the 1994 Tisdall Award Competition, The Hospital for Sick Children,Department of Pediatrics, June 1994.

• Canadian Association of Gastroenterology/Industry Fellowship Award, July 1, 1992to June 30, 1993.

• Canadian Association of Gastroenterology Award for "Outstanding Presentation" atthe 2nd Annual Postgraduate Course in Gastroenterology, St. Adele, Quebec,March 1993.

• Chief Resident of Pediatrics, Children's Medical Center of Brooklyn, July 1990 toJune 1991.

• "Contenta Award" for occupying first place in a class of 75 in medical school.

Board Certification Board certified in Pediatric Gastroenterology, 1997, recertified in 2004, 2011 and 2014Board certified in Pediatrics, 1992, recertified in 2001 Bibliography and products of scholarship Peer reviewed book chapters

• Francisco A. Sylvester. Inflammatory Bowel Diseases and Skeletal Health, In:Pediatric Inflammatory Bowel Disease. P Mamula, AB Grossman, RNBaldassano, JR Kelsen, JE Markowitz (Editors). Springer International PublishingAG 2017.

• Anam Fatima, Francisco A. Sylvester. The Gut Microbiome and Probiotics. In: JRRosh, L.A. Heitlinger, WD Rosenfeld (Guest Editors). Adolescent Medicine Stateof the Art Reviews. Clinical GI Challenges in the Adolescent. 2016;27(1): 140-154. American Academy of Pediatrics.

• Francisco A. Sylvester. Effects of Digestive Diseases on Bone Metabolism: InPediatric Gastrointestinal and Liver Disease, 5th edition, 2016. Edited by JeffreyS. Hyams, Marha Kay, Robert Wyllie, Elsevier, pages 1132-1141

• Sylvester FA, Wershil B. Food Allergy. In: Shaoul R, editor. Practical Algorithmsin Pediatric Gastroenterology. S Karger Publishing; 2014. Pages 6-8.

• Sylvester FA, Turck D. Lower Gastrointestinal Bleeding. In: Shaoul R, editor. Practical Algorithms in Pediatric Gastroenterology. S Karger Publishing; 2014.Pages 14-16.

• Sylvester FA, Zeisler B. Protein Losing Enteropathy. In: Shaoul R, editor. Practical Algorithms in Pediatric Gastroenterology. S Karger Publishing; 2014.Pages 48-50.

• Sylvester FA, Zeisler B. Gastrointestinal Polyps. In: Shaoul R, editor. PracticalAlgorithms in Pediatric Gastroenterology. S Karger Publishing; 2014. Pages 54-56.

• Sylvester FA, Wynn EL. Pediatric Bone and Adult Bone: Physiological Differencesin Pediatric Drug Development: Concepts and Applications, 2nd Edition (edsMulberg, Murphy, Dunne, Mathis), John Wiley & Sons 2013, pages 395-408.

• Sylvester FA, Vella AT Inflammatory bowel disease and bone. InOsteoimmunology: Interactions of the Immune and Skeletal Systems. Edited byJoseph Lorenzo, Yongwon Choi, Mark Horowitz, Hiroshi Takayanagi. Elsevier2010, pages 325-342

• Sylvester FA. Bone and digestive disorders: In Pediatric Gastrointestinal Disease,pathophysiology, diagnosis, management, 4th edition, 2011. Edited by Robert

pathophysiology, diagnosis, management, 4th edition, 2011. Edited by RobertWyllie, Jeffrey S. Hyams. Elsevier, pages 1012-1019

• Sylvester FA. Protein-losing enteropathy: In Pediatric Gastrointestinal Disease,pathophysiology, diagnosis, management, 4th

edition, 2011. Edited by RobertWyllie, Jeffrey S. Hyams. Elsevier, pages 360-365

• Sylvester FA Bone and Inflammatory Bowel Disease. In: The Changing World ofInflammatory Bowel Disease, 2009. Edited by Ellen J Scherl, MD, FACP, AGAFand Marla C. Dubinsky, MD. Slack Incorporated, pages 101-118.

• Emerick K, Sylvester FA. Gastrointestinal and Liver Disorders. In: NMS Pediatrics5th

Edition, 2008. Edited by Paul Dworkin and Paula Algranati. Walter KluwerHealth– Lippincott, Williams & Wilkins, pages 246-270

• Sylvester FA. Effects of digestive diseases on bone metabolism: In PediatricGastrointestinal Disease, pathophysiology, diagnosis, management, 3rd edition,2006. Edited by Robert Wyllie, Jeffrey S. Hyams. Saunders, pages 1177-1190

• Sylvester FA. Protein-losing enteropathy: In Pediatric Gastrointestinal Disease,pathophysiology, diagnosis, management, 3rd

edition, 2006. Edited by RobertWyllie, Jeffrey S. Hyams. Saunders, pages 507-515

• Langman CB, Levine M, Sylvester F. Osteoporosis in Children and Adolescents.National Osteoporosis Foundation Newsletter, Fall 2005.

• Sylvester FA. Peptic Ulcer Disease (Chapter 316) In: Nelson Textbook ofPediatrics, 17th

Edition, 2003. Edited by Richard Behrman, Robert Kliegman, HalB. Jenson. Saunders, pages 1197-1198

• Sylvester FA. Other diseases of the esophagus. In: Pediatric GastrointestinalDisease: pathophysiology, diagnosis, management, 2nd edition, 2003. Edited byRobert Wyllie, Jeffrey S. Hyams. Saunders, pages 199-204

• Sylvester FA, Hyams JS. Appropriate use of corticosteroids in inflammatory boweldisease. In Bayless T, Hanauer S. Advanced therapy of inflammatory boweldisease. B.C. Decker, Hamilton, Ontario, 2001, pages 363-66.

• Forstner JF, Oliver MG, Sylvester F. Production, structure and biologic relevanceof gastrointestinal mucins. In: Infections of the Gastrointestinal Tract, Editor: J.I.Ravdin. Raven Press, New York, 1995, pages: 71-88.

Peer reviewed journal articles – original research

• Subra Kugathasan, Lee A Denson, Thomas D Walters, Mi-Ok Kim, Urko MMarigorta, Melanie Schirmer, Kajari Mondal, Chunyan Liu, Anne Griffiths, JoshuaD Noe, Wallace V Crandall, Scott Snapper, Shervin Rabizadeh, Joel R Rosh,Jason M Shapiro, Stephen Guthery, David R Mack, Richard Kellermayer, MichaelD Kappelman, Steven Steiner, Dedrick E Moulton, David Keljo, Stanley Cohen,Maria Oliva-Hemker, Melvin B Heyman, Anthony R Otley, Susan S Baker,Jonathan S Evans, Barbara S Kirschner, Ashish S Patel, David Ziring, Bruce CTrapnell, Francisco A Sylvester, Michael C Stephens, Robert N Baldassano,James F Markowitz, Judy Cho, Ramnik J Xavier, Curtis Huttenhower, Bruce JAronow, Greg Gibson, Jeffrey S Hyams, Marla C Dubinsky. Prediction ofcomplicated disease course for children newly diagnosed with Crohn’s disease: amulticentre inception cohort study. The Lancet http://dx.doi.org/10.1016/S0140-6736(17)30317-3

• Wael N Sayej, Antoine Ménoret, Anu S Maharjan, Marina Fernandez, Zhu Wang,Fabiola Balarezo, Jeffrey S Hyams, Francisco A Sylvester and Anthony T Vella.Characterizing the inflammatory response in esophageal mucosal biopsies inchildren with eosinophilic esophagitis. Clinical & Translational Immunology (2016)5, e88; doi:10.1038/cti.2016.30

• Wang X, Yamamoto Y, Wilson LH, Zhang T, Howitt BE, Farrow MA, Kern F, Ning G,

• Wang X, Yamamoto Y, Wilson LH, Zhang T, Howitt BE, Farrow MA, Kern F, Ning G,Hong Y, Khor CC, Chevalier B, Bertrand D, Wu L, Nagarajan N, Sylvester FA,Hyams JS, Devers T, Bronson R, Lacy DB, Ho KY, Crum CP, McKeon F, Xian W.Cloning and variation of ground state intestinal stem cells. Nature.2015;522(7555):173-8

• Hommel KA, Gray WN, Hente E, Loreaux K, Ittenbach RF, Maddux M, BaldassanoR,Sylvester F, Crandall W, Doarn C, Heyman MB, Keljo D, Denson LA. TheTelehealthEnhancement of Adherence to Medication in Pediatric IBD (TEAM) Trial: DesignandMethodology. Contemp Clin Trials 2015 43:105-113.

• Sylvester FA, Draghi A, Menoret A, Fernandez ML, Wang Z, Vella AT. A DistinctiveColonic Mucosal Cytokine Signature in New Onset, Untreated Pediatric CrohnDisease. J Pediatr Gastroenterol Nutr. 2014; 59:553-61

• Chicaiza H, Hellstrand K, Lerer T, Smith S, Sylvester F. Potassium Hydroxide: AnAlternative Reagent to Perform the Modified Apt Test. J Pediatr 2014Sep;165(3):628-30

• Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B,Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C,González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M,Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S,Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. The treatment-naïvemicrobiome in new-onset Crohn's disease. Cell Host Microbe. 2014 Mar12;15(3):382-92.

• Martin DA, Taheri R, Brand MH, Draghi II A, Sylvester FA, Bolling BW.Antiinflammatory activity of aronia berry extracts in murine splenocytes. Journalof Functional Foods 2014; 8:68-75.

• Sylvester FA, Turner D, Draghi A 2nd, Uuosoe K, McLernon R, Koproske K, MackDR, Crandall WV, Hyams JS, Leleiko NS, Griffiths AM. Fecal osteoprotegerinmay guide the introduction of second-line therapy in hospitalized children withulcerative colitis. Inflamm Bowel Dis. 2011;17(8):1726-30.

• Goh VL, Estrada DE, Lerer T, Balarezo F, Sylvester FA*. Effect of Gluten-FreeDiet on Growth and Glycemic Control in Children with Type 1 Diabetes andAsymptomatic Celiac Disease. Journal of Pediatric Endocrinology & Metabolism2010; 23(11):1169-73.

• Bennett Jr. WE, González-Rivera R, Puente BN, Shaikh N, Stevens HJ, MooneyJC, Eileen, Klein EJ, Denno DM, Draghi II A, Sylvester FA, Tarr PI.Proinflammatory fecal mRNA and childhood bacterial enteric infections. GutMicrobes 2010; 1(4):209-212.

• Sylvester FA*, Leopold S, Lincoln M, Hyams JS, Griffiths AM, Lerer T. A two-yearlongitudinal study of persistent lean tissue deficits in children with Crohn'sdisease. Clin Gastroenterol Hepatol. 2009 Apr;7(4):452-5.

• Sylvester FA*, Wyzga N, Hyams JS, Lerer, T, Vance K, Hawker G, Griffiths AM.Natural History of Bone Metabolism and Bone Mineral Density in Children withInflammatory Bowel Disease. Inflamm Bowel Dis 2007;13(1):42-50.

• Sylvester FA*, Davis PM, Wyzga N, Hyams JS, Lerer T. Are activated T cellsregulators of bone metabolism in children with Crohn disease? J Pediatr2006;148(4):461-466.

• Wyzga N, Varghese S, Wikel S, Canalis E, Sylvester FA*. Effects of activated Tcells on osteoclastogenesis depend on how they are activated. Bone

cells on osteoclastogenesis depend on how they are activated. Bone2004;35(3):614-20.

• Varghese S, Wyzga N, Griffiths AM, Sylvester FA*. Effects of serum from childrenwith newly diagnosed Crohn disease on primary cultures of rat osteoblasts. JPediatr Gastroenterol Nutr. 2002;35(5):641-8.

• Sylvester FA*, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease onbone metabolism in vitro: a role for interleukin-6. J Bone Miner Res.2002;17(4):695-702.

• Hyams JS, Davis P, Sylvester FA, Zeiter DK, Justinich CJ, Lerer T. Dyspepsia inchildren and adolescents: a prospective study. J Pediatr Gastroenterol Nutr.2000;30(4):413-8.

• Sajjan US, Sylvester FA, Forstner JF. Cable-piliated Burkholderia cepacia binds tocytokeratin 13 of epithelial cells. Infect Immun. 2000 Apr;68(4):1787-95.

• Sylvester FA, Sajjan US, Forstner JF: Burkholderia (Basonym Pseudomonas)cepacia binding to lipid receptors. Infection & Immunity 1996; 64(4):1420-1425.

• Sylvester FA, Shuckett B, Cutz E, Durie PR, Marcon M. Management of fibrosingpancreatitis in childhood presenting with obstructive jaundice. Gut 1998; 43:715-20.

• Sylvester FA, Gold B, Lastovica A, Sherman P, Forstner JF: Adherence to lipidsand intestinal mucin by a recently recognized human pathogenCampylobacterupsaliensis. Infection & Immunity 1996;64(10):4060-4066.

• Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P: Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease.Journal of Pediatric Gastroenterology and Nutrition 1993; 17: 186-192.

Peer reviewed journals – invited articles and editorials

• Sylvester FA. The ABCs (and Ds) of Bone Imaging in Children with CrohnDisease. J Pediatr Gastroenterol Nutr. 2016 Feb 5. [Epub ahead of print]PubMed PMID: 26859087

• Sylvester FA. Effects of exclusive enteral nutrition on bone mass, linear growthand body composition in children with Crohn's disease. Nestle Nutr InstWorkshop. 2014;79:125-30. doi: 10.1159/000360717. Epub 2014 Sep 5. PubMedPMID: 25227300.

• Bianchi ML, Leonard MB, Bechtold S, Högler W, Mughal MZ, Schönau E,Sylvester FA, Vogiatzi M, van den Heuvel-Eibrink MM, Ward L. Bone health inchildren and adolescents with chronic diseases that may affect the skeleton: the2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014 Apr-Jun;17(2):281-94 PMID: 24656723.

• Sylvester FA, Gordon CM, Thayu M, Burnham JM, Denson LA, Essers J, FerrariS, Gupta N, Hewison M, Koletzko S, McCabe L, Pappa H, Sanderson I, Ward L,Zanotti S. Report of the CCFA pediatric bone, growth and muscle healthworkshop, New York City, November 11-12, 2011, with updates. Inflamm BowelDis. 2013;19(13):2919-26. PubMed PMID: 23974992.

• Rufo PA, Denson LA, Sylvester FA, Szigethy E, Sathya P, Lu Y, Wahbeh GT, SenaLM, Faubion WA. Health Supervision in the Management of Children andAdolescents with Inflammatory Bowel Disease - recommendations of the NorthAmerican Society for Pediatric Gastroenterology, Hepatology, and Nutrition(NASPGHAN). J Pediatr Gastroenterol Nutr. 2012;55(1):93-108.

• Ngoi SM, Sylvester FA, Vella AT. The role of microbial byproducts in protectionagainst immunological disorders and the hygiene hypothesis. Discov Med.

against immunological disorders and the hygiene hypothesis. Discov Med.2011;12(66):405-12.

• Pappa H, Thayu M, Sylvester F, Leonard M, Zemel B, Gordon C. Skeletal healthof children and adolescents with inflammatory bowel disease. J PediatrGastroenterol Nutr. 2011;53(1):11-25.

• Sylvester FA. The Impact of Gastrointestinal and Liver Diseases on Bone: It Ain’tLike Menopause! Gastroenterology 2011;140(1):22-5.

• Viswanathan A, Sylvester FA*. Chronic pediatric inflammatory diseases: effects onbone. Rev Endocr Metab Disord. 2008;9(2):107-22.

• Sylvester FA. Does bone crack under the effects of IBD in children? Editorial. JPediatr Gastroenterol Nutr 43:563-5, 2006.

• NASPGHAN Nutrition Report Committee: Michail S, Sylvester F, Fuchs G,Issenman R. Clinical Efficacy of Probiotics: Review of the Evidence With Focuson Children. J Pediatr Gastroenterol Nutr 2006;43:550-557.

• Bousvaros A, Sylvester F, et al. Challenges in Pediatric Inflammatory BowelDisease. Inflammatory Bowel Diseases 2006;12:885-913.

• Sylvester FA. IBD and skeletal health: children are not small adults! InflammBowel Dis. 2005;11(11):1020-3.

• Sylvester FA. Cracking the risk of fractures in Crohn disease. Selected Summary.J Pediatr Gastroenterol Nutr 2004;38(1):113-4.

• Sylvester FA. Bone abnormalities in gastrointestinal and hepatic disease. RevEndocr Metab Disord. 2001 Jan;2(1):75-80.

• Sylvester FA. An update on bone abnormalities in gastrointestinal and liverdisease. The Endocrinologist 2001;11(2):77-80.

• Sylvester FA. Bone abnormalities in gastrointestinal and hepatic disease. CurrOpin Pediatr. 1999 Oct;11(5):402-7.

• Sylvester FA, Griffiths AM: Endothelins and the color of mice: unraveling theetiopathogenesis of Hirschprung disease (Selected Summary). Journal ofPediatric Gastroenterology & Nutrition, 1995;21:478-479.

Peer reviewed journals – case reports

• Francolla KA, Altman A, Sylvester FA. Hemophagocytic syndrome in anadolescent with Crohn disease receiving azathioprine and infliximab. J PediatrGastroenterol Nutr 2008;47(2):193-5.

• Sylvester F. A rare of chronic granulomatous disease presenting as inflammatorybowel disease. Canadian Journal of Gastroenterology 1996;10(4):221-224.

Doctoral thesis (MD degree) Sylvester F: Polymyositis and Dermatomyositis in Childhood: a study of 13 patients inthe Cayetano Heredia Hospital. Thesis for Medical Doctor, 1985. Peer reviewed oral presentations at national meetings

• Wa Xian, Jeffrey S. Hyams, Frank D. McKeon, Francisco Sylvester, Khek-Yu Ho,Jason K. Hou. Epigenetic Alterations in Mucosal Stem Cells in Pediatric Crohn'sDisease. Digestive Diseases Week, Chicago, May 2017

• Wa Xian, Francisco Sylvester, Jason K. Hou, Jeffrey S. Hyams, Khek-Yu Ho,Frank D. McKeon. Cloning Colonic Stem Cells of Ulcerative Colitis Patients from

Frank D. McKeon. Cloning Colonic Stem Cells of Ulcerative Colitis Patients fromEndoscopic Biopsies. Digestive Diseases Week, Chicago, May 2017

• Subra Kugathasan, Lee A. Denson, Thomas D. Walters, Mi-Ok Kim, UrkoMarigorta, Melanie Schirmer, Kajari Mondal, Chunyan Liu, and others (FSylvester). Early Anti-TNF is Effective in Preventing Internal Penetrating but notStricturing Disease Complications in Children Newly Diagnosed with Crohn'sDisease: A Prospective Risk Prediction Model for Disease Behavior Study.Digestive Diseases Week, Chicago, May 2017

• Sylvester F et al. Inflammatory Bowel Disease Impairs the Regenerative Capacityof Skeletal Muscle Stem Cells. Digestive Diseases Week, Chicago, May 2014.

• Sylvester F et al. 12-hour bowel prep with polyethylene glycol 3350 is effective,well tolerated and safe in children, Digestive Diseases Week, San Diego, CA,May 2012.

• Sylvester F et al. The immunophenotype of the colonic mucosa in children withIBD in deep remission: healed is distinct from healthy, CA, May 2012.

• Sylvester F et al. Osteoprotegerin expression is upregulated in the colon ofchildren with active inflammatory bowel disease, CA, May 2012.

• Sylvester F, Hyams J, Lerer T, Lincoln M, Griffiths AM. Profound Lean Body MassDeficits in Children with Crohn Disease: A 2-Year Longitudinal Study fromDiagnosis. Digestive Diseases Week (DDW), Washington DC, May 2007.

• FA Sylvester, N Wyzga, S Vargehese, AD Levine. IL-10 knockout mice as a modelof osteoporosis in inflammatory bowel disease. Oral presentation at DDW, May2002, San Francisco, CA.

• FA Sylvester, JS Hyams, CJ Justinich, DK Zeiter, K Harris, J Avolio, G Hawker,AM Griffiths. Longitudinal follow-up of bone mineral density in children withCrohn’s disease from the time of diagnosis. Oral presentation at DDW, SanDiego, CA, May 2000.

• FA Sylvester, JS Hyams, C Justinich, D Zeiter, P Davis, K Harris, J Avolio, GHawker, AM Griffiths. Osteopenia is frequent in children with Crohn’s disease atdiagnosis. Oral presentation at the Annual Meeting of the North AmericanSociety For Pediatric Gastroenterology and Nutrition. Denver, Colorado, October1999.

• Sylvester FA, Sajjan US, Forstner, JF. Pseudomonas cepacia bind toglobotriosylceramide (Gb3). The American Pediatric Society and The Society forPediatric Research Meeting, May 1993. Oral presentation.

Invited presentations

• Second LASPGHAN Junior School. Inflammatory bowel disease: Presentation andDiagnosis; Inflammatory bowel disease: Management of the patient who is notdoing well; Eosinophilic gastrointestinal disease; Crohn’s disease: induction ofremission pro vs con enteral nutrition/steroids; discussion of cases of abdominalpain; Santiago, Chile, December 2016.

• Gastrointestinal Emergencies. Pinehurst Pediatric Symposium, November 2016.

• Advances in the Treatment of Inflammatory Bowel Disease: The Future is Now.Peruvian American Endowment Annual Scientific Meeting, Miami MarriottBiscayne Bay, October 2016

• All Roads Lead To Rome (And To The GI tract). Pediatric Grand Rounds, UNCChapel Hill, August 2016

• IBD in adolescents – pertinent issues and what adult GI providers should know.2016 North Carolina Society for Gastroenterology meeting, Pinehurst, NC

2016 North Carolina Society for Gastroenterology meeting, Pinehurst, NCFebruary 2016.

• DXA for children with IBD: for all or for none? Pediatric IBD Research Day, WeillCornell Medical Center, September 18, 2015.

• New advances in the pathophysiology of IBD; Stem cells and IBD; BiologicalTherapy in IBD. XXV International Course of the Peruvian-Japanese Polyclinic.Lima – Peru, April 2015

• Bone Health in Children with IBD. Department of Pediatrics Hadassah UniversityHospitals, Jerusalem, Israel, January 2015.

• Health Maintenance in Children and Young Adults with IBD. Advances in PediatricGastroenterology, Hepatology and Nutrition - sponsored by Harvard MedicalSchool/Boston Children’s Hospital, Boston, April 2014.

• Taking care of the adolescent with IBD – Great Debates in Inflammatory BowelDisease – San Francisco, California, March 2014.

• Effects of Exclusive Enteral Nutrition on Bone Mass, Linear Growth and BodyComposition in Children with Crohn disease. "Nutrition, Gut Microbiota andImmunity: Therapeutic Targets for IBD” 79th Nestlé Nutrition Institute Workshop –New York, NY, September 2013.

• Making Bones Stronger – 10th Advances in Pediatric Nutrition Course, Johns

Hopkins University, Baltimore, Maryland, October 2011.• “Bone and vitamin D” and “IBD and Nutrition”. Neonatal and Pediatric Nutrition

Conference (sponsored by University of California, San Diego): Update 2011,San Diego July 2011.

• Pediatric IBD: “Should we abandon steroid therapy?” and “How to optimallymaintain skeletal health.” Great Debates and Updates in Inflammatory BowelDisease, New York, NY April 2011.

• From Gut to Bone and Back: What We Are Learning From Inflammatory BowelDisease - GCRC Seminar Series – University of Connecticut Health Center –February 22, 2011.

• Bone Health in Pediatric IBD; Advise For Clinicians From Clinicians: Webinarsponsored by CDHNHF and NASPGHAN – December 6, 2010.

• Inflammatory bowel disease - II Workshop LATAM Nutrition Nestle Institute 2010,Riviera Maya, Mexico, November 2010.

• Management of severe ulcerative colitis in children, NASPGHAN Annual Meeting,New Orleans, LA, October 22, 2010.

• “International Course of Pediatric Gastroenterology and Hepatology” organized bythe Peruvian Society of Pediatrics. 3 lectures: constipation, eosinophilicesophagitis and pediatric inflammatory bowel disease. Lima, Peru May 28, 2010.

• Neonatal and Pediatric Nutrition Conference, “Health Benefits of Vitamin D” and“Nutritional Challenges in Pediatric Inflammatory Bowel Diseases”, SanFrancisco, CA. July 20-22, 2009.

• Baystate Health Continuing Education, Pediatric Nutrition. “Vitamin Update: Focuson Vitamin D Deficiency. June 3, 2009, Holyoke, MA.

• New York Gut Club, sponsored by New York Presbyterian-Weill Cornell MedicalCollege “Bone Health in Inflammatory Bowel Diseases”, April 29, 2009.

• CCFA Advances in Inflammatory Bowel Diseases - Clinical and ResearchConference, Hollywood, FL. I gave two talks: Growth and Skeletal Health inPediatric IBD (Satellite Symposium) and Bone health in children and adults withIBD (Plenary talk). December 4-7, 2008.

• Pediatric Course,” Abdominal pain”, “Chronic diarrhea”, sponsored by Universidad

• Pediatric Course,” Abdominal pain”, “Chronic diarrhea”, sponsored by UniversidadPeruana Cayetano Heredia, Lima, Peru, April 28, 2007.

• 25th Peruvian Congress of Gastroenterology – Lima, Perú, November, 2004. Three

talks: New therapies for inflammatory bowel disease; Gastrointestinalmanifestations of food allergy in children; Gastrointestinal syndromes in cysticfibrosis.

• Annual Pediatric Update Course, Danbury Hospital, Danbury, CT, November 2004.Make no bones about it, osteoporosis is a pediatric disease!

Invited oral presentations at professional conferences

• Extraintestinal manifestations in pediatric IBD - a survey of conditions andtreatments: Growth and bone development. Advances in Inflammatory BowelDiseases, Orlando, FL December 2016

• Translational pediatric IBD: The year in review. Advances in Inflammatory BowelDiseases, Orlando, FL December 2016

• Challenges in pediatric IBD: what are the best approaches to manage severe,newly diagnosed patients or those with refractory disease? Advances inInflammatory Bowel Diseases, Orlando, FL December 2016

• Induction of remission in children with inflammatory bowel disease: glucocorticoids.World Congress of Pediatric Gastroenterology, Hepatology and Nutrition,Montreal, Canada, October 2016

• Patients with Crohn’s disease and growth failure should be managed with "topdown" therapy: Biologics first; Severe, refractory, hospitalized ulcerative colitispatients should only be treated with medical therapy; Meet the Professor:Approach to the treatment of children with severe ulcerative colitis. 2015Advances in Inflammatory Bowel Diseases, Orlando, FL. December, 11-13, 2015

• What is new in inflammatory bowel disease in pediatrics; Bi-annual meeting of theLatin American Society of Pediatric Gastroenterology, Hepatology and Nutrition(LASPGHAN), Lima, Peru November 22, 2015

• Chronic diarrhea – North and South; LASPGHAN, Lima, Peru November 22, 2015

• Bone proteins in the gut: from bench to bedside and back, Annual conference ofThe Israeli Association for Pediatric Gastroenterology and Nutrition, Ashkelon,Israel, January 2015.

• “Clostridium difficile”. LASPGHAN session, NASPGHAN Annual Meeting, Atlanta,October 2014.

• “Basic Research in Pediatric IBD: Research lessons learned” - State of the ArtResearch Lecture, NASPGHAN Annual Meeting, Chicago, October 2013.

• “Biological therapy of IBD”. “Bone pathology in gastrointestinal diseases.” IICongress of Pediatric Gastroenterology, Hepatology and Nutrition – Viña del Mar,Chile, August 2013.

• “Eosinophilic esophagitis”, “Inflammatory bowel disease – diagnosis”,“Inflammatory bowel disease – treatment”, “Intestinal rehabilitation”, “Bone massin chronic gastrointestinal diseases” XXIII Peruvian Congress of DigestiveDiseases. Lima, Peru, June 27 – 30, 2012.

• “Impact of gastrointestinal and liver diseases on bone mass” and “Low bonedensity in Crohn disease: How to treat? 14th Congress of PediatricGastroenterology, Sao Paolo, Brazil, June 5 – 9, 2012.

• “The Intestine, its bacteria and inflammation: a 2-way conversation” CONAPAME(Annual National Mexican Congress of Pediatrics), Mexico, DF April 2012.

• “Inflammatory Bowel Disease”, LASPGHAN session in the 2011 NASPGHAN

• “Inflammatory Bowel Disease”, LASPGHAN session in the 2011 NASPGHANmeeting, Orlando, FL October 2011.

• “Skeletal Health 2011 – Unearthing the Updates”, NASPGHAN PostgraduateCourse, Orlando, FL October 2011.

• “The Biology of Gastrointestinal Inflammation and its Impact on the SkeletalSystem” Digestive Diseases Week, Chicago, IL, May 9, 2011.

• “Osteoporosis and Arthritis in IBD: Diagnosis and Management” DigestiveDiseases Week, New Orleans, LA, May 4, 2010.

• “Latin American Congress of Pediatric Gastroenterology, Hepatology andNutrition”, organized by SLAGHNP and LASPGHAN; 2 lectures: bone health inpediatric inflammatory bowel disease and pathogenesis of pediatric inflammatorybowel disease. Puerto Varas, Chile November 25-28, 2010.

• Plenary session I: “Global trends in Pediatric Inflammatory Bowel Disease”. IIIWorld Congress of Pediatric Gastroenterology & Nutrition, Foz de Iguazu, Brazil,August 2008.

• “Pathogenesis of bone loss in IBD”. NASPGHAN Postgraduate Course, Salt LakeCity, Utah, October 2007.

• “Effect of Pediatric Inflammatory Bowel Disease on Bone Metabolism”. FourthInternational Conference on Children's Bone, Montréal, Canada, June 22, 2007.

• Plenary talk, “Bone and Pediatric Illness: Lessons from Crohn’s Disease”. PediatricBone and Mineral Working Group at the Annual meeting of the American Societyfor Bone & Mineral Research, Philadelphia PA, September 2006.

• Digestive Disease Week, invited talk 'Bad to the Bone' Effects IBD on Bone Growthand Maintenance, Los Angeles, May 2006.

• Invited faculty, NASPGHAN Postgraduate course “Bone and Crohn disease”,October 2005.

• 3rd World Congress of Pediatric Gastroenterology, Hepatology & Nutrition, Paris,France, July 2004. Bone abnormalities in gastrointestinal and liver diseases.

• Osteoporosis in Inflammatory Bowel Diseases. 3rd International Congress onGlucocorticoid Induced Osteoporosis, under the auspices of the InternationalOsteoporosis Foundation, Turin, Italy March 8, 2003.

• An update on the effects of gastrointestinal disease in bone (sponsored byWomen’s Health Committee). Invited presentation at Digestive Diseases Week,May 2002, San Francisco, CA.

• Panel discussion on Osteoporosis in GI and Liver Disease (along with Dr. TheresaPizarro, Dr. Sunanda Kane, Dr. Charles Bernstein). At Digestive Diseases Weeklive! (Live programming at the Annual Meeting of the North AmericanGastroenterological Association, May 2002, San Francisco, CA featuring “thebest science from the top DDW newsmakers”).

• Invited debate with Anne M. Griffiths MD, MRCP(C) at the Annual Meeting of theNorth American Society for Pediatric Gastroenterology, Hepatology, and Nutrition(NASPGHAN) in Orlando, FL, October 2001: “Pediatric Gastroenterologists needto know about bone densities!”

Other

• Invited panelist: All Sides with Ann Fisher” (http://radio.wosu.org/programs/all-sides-ann-fisher) to discuss to gut microbiome October 07, 2015

• Invited faculty, CCFA Parents, Teens and Kids Workshop, Illinois Chapter CCFAPatient and Professional Educational Symposium, Chicago, IL 4/21/12.

Patient and Professional Educational Symposium, Chicago, IL 4/21/12.• Chair, Pediatric IBD Clinical and Translational Studies Topic Forum, Digestive

Diseases Week, Chicago, IL 2011.• Chair, Pediatric IBD: Clinical and Translational Studies, Digestive Diseases Week,

New Orleans, LA, May 3, 2010.• Invited faculty, NASPGHAN-Nestle 1st year Fellows Conference, Fort Lauderdale,

FL January 20-23, 2009.• Invited faculty, NASPGHAN Postgraduate Course. “Vitamin D – It’s not just for the

bones”, San Diego, CA, November 13, 2008.• Invited faculty, NASPGHAN-Nestle 1st year Fellows Conference, Fort Lauderdale,

FL January 17-21, 2008.• Invited expert panelist, International Society for Clinical Densitometry (ISCD),

Pediatric Position Development Conference, Montreal, Canada June 19-21,2007.

• Invited faculty, NASPGHAN-Nestle 1st year Fellows Conference, Miami, FLJanuary 2007.

• Invited faculty, Pediatric IBD Fellows Meeting, Santa Monica, CA April 2006.

• Invited faculty, NASPGHAN-Nestle 1st year Fellows Conference, Key Biscayne, FLJanuary 19-22, 2006.

• Invited faculty. “Bone Health in Pediatric Illness” June 2004. “From Critical Care toHome Care: Challenges in Nutrition Support”. Connecticut Chapter of ASPEN.

• Invited faculty. The Intestine, Just another Long Bone? April, 2004Ross/NASPGHAN 2nd Year Pediatric GI Fellows Seminar, Carefree, ArizonaApril 1-4, 2004.

• ENT Manifestations of Gastroesophageal Reflux: True or Ballyhoo?Otolaryngology Seminar, CCMC, May 2002.

• IBD and Me! Sponsored by the Long Island Chapter of Crohn’s & ColitisFoundation of America. Talk to parents and children with inflammatory boweldisease about osteoporosis associated with Crohn’s disease, September 2000and 2001.

• 3rd Annual “Kids Count” Weekend Program: Growing up with IBD. Talk: Bonedisease and Crohn’s. April 9, 2000.

• Crohn’s disease and osteopenia. Long Island Jewish Medical Center, Crohn’s &Colitis Foundation of America, Long Island Chapter, Board of Trustees Meeting.March 25, 1998.

• Helicobacter pylori: new advances. New Britain General Hospital, March 24, 1998.

• Gastroesophageal reflux in neonates and premature babies. 8th AnnualNeonatology Conference, Wequassett Inn, Chatham, Massachusetts. September29, 1997.

• Chronic diarrhea. Workshop at the Pediatric Clinical Update Symposium,Connecticut Children’s Medical Center, Hartford. June 15, 1996.

Poster presentations at national meetings

• Maharjan A, Francisco A. Sylvester et al. Effects of Crohn’s Disease FecalMicrobial Transplant on Bone Mass of Germ-Free Mice Are Independent ofGastrointestinal Inflammation American Society for Bone and Mineral ResearchAnnual Meeting 2017 Annual Meeting, September 8-11, 2017 at the ColoradoConvention Center in Denver, Colorado, USA

• Maharjan A, Francisco A. Sylvester et al. Intestinal microbiome present in Crohndisease impairs skeletal health and linear growth (Plenary Poster). AmericanSociety for Bone and Mineral Research Annual Meeting. Atlanta, Georgia.September 2016.

• Maharjan A et al. Francisco A. Sylvester et al. Colonic Osteoprotegerin (OPG)participates in Innate Immune Responses to Luminal Bacteria Presentation.American Society for Bone and Mineral Research Annual Meeting. Atlanta,Georgia. September 2016

• Sylvester F et al. Normal Programmed Death-1 Expression In Peripheral Blood TCells, But Not Monocytes In Children With New Onset Crohn Disease; ColonicOsteoprotegerin: Higher Expression in Children with Ulcerative Colitis than Crohndisease; Increased Serum Lipopolysaccharide In Crohn Disease Is AssociatedWith Alterations in Toll-Like Receptor Expression in Peripheral Blood. DigestiveDiseases Week, May 2014, Chicago, Illinois.

• Sylvester F et al. Innate Immune Cytokines Characterize Colonic Inflammation InNewly Diagnosed Inflammatory Bowel Disease; Reciprocal Regulation of ColonicEpithelial Cell Secretion of Osteoprotegerin by Inflammasome Cytokines;"Osteoprotegerin: A Component Of The Colonic Epithelial Cell Barrier" DigestiveDiseases Week, May, 2013, Orlando, Florida.

• Andrew Draghi, Robert Clark, Anthony T Vella, David Mack, Leanne Ward,Catherine Adams, Francisco Sylvester. Proinflammatory Cytokine Expression inBone Marrow of Colitic Mice and Children with Crohn Disease American Societyfor Bone & Mineral Research, Toronto, ON September 2010.

• Francisco A. Sylvester, Dan Turner, Andrew Draghi, Krista Uuosoe, Robin A.MacLernon, Anne M. Griffiths. Fecal Osteoprotegerin Predicts the Need forSecond Line Therapy in Hospitalized Children with Ulcerative Colitis, DigestiveDiseases Week, New Orleans, LA May 2010.

• Anu Viswanathan, Sevket Yigit, Miriam Lincoln, Francisco Sylvester. Vertebralfracture assessment in children with inflammatory bowel disease. Annualmeeting of the American Society for Bone & Mineral Research, Denver, COSeptember 2009.

• Anu Viswanathan, Andrew Draghi II, Ernesto Canalis, Francisco Sylvester. TumorNecrosis Factor- α Inhibits Osteoblast Differentiation by Inhibiting Wnt Signalingposter presented at ENDO 09 (annual meeting of the Endocrine Society),Washington, DC June 10-13, 2009.

• Vi Lier Goh, D. Elizabeth Estrada, Trudy Lerer, Francisco A. Sylvester. Effect ofGluten-Free Diet on Growth and Glycemic Control in Children with Type 1Diabetes and Asymptomatic Celiac Disease. Poster at DDW, Chicago, IL, May2009.

• F Sylvester, N Wyzga. Interferon-γ Attenuates BMP-2 Signaling via Stat-1 Bindingof Smad4 in the Cytoplasm. Annual meeting of the American Society for Bone &Mineral Research, Montreal, Canada September 2008.

• F Sylvester, M Lincoln, L Fourman, K O'Brien. Pediatric Crohn Disease IsAssociated with Negative Calcium Balance and Increased Renal Losses OfCalcium. Poster at the Annual meeting of the American Society for Bone &Mineral Research, Montreal, Canada September 2008.

• Yigit S, McKinney B, Pedersen J, Draheim B, Sylvester F. Is Vitamin D DeficiencyMore Common in Children with Cerebral Palsy than in Healthy Children? Posterat the Annual meeting of the American Society for Bone & Mineral Research,Montreal, Canada September 2008.

• A Skinner, T Lerer, N Wyzga, A Viswanathan, F. Sylvester. Fecal Osteoprotegerin:A Marker for Pediatric Ulcerative Colitis At Diagnosis – a Pilot Study. Poster at

A Marker for Pediatric Ulcerative Colitis At Diagnosis – a Pilot Study. Poster atDDW, San Diego, CA, May 2008.

• L. Bustamante-Romero, N Wyzga, F Sylvester. IL-10 Inhibits Different MouseOsteoclast Precursors In Vitro. Annual meeting of the American Society for Bone& Mineral Research, Philadelphia PA, September 2006.

• S. Varghese, N. Wyzga, F. Sylvester. Inhibition of bone formation by activated Tlymphocytes is partly mediated through interferon-γ (Plenary poster). Annualmeeting of the American Society for Bone & Mineral Research, Nashville TN,September 2005.

• Sylvester FA, Davis PM, Wyzga N, Hyams JS, Lerer T. Activated T cells: regulatorsof bone metabolism in children with Crohn disease? Annual meeting of theAmerican Society for Bone & Mineral Research, Nashville TN, September 2005.

• F. A. Sylvester, J. S. Hyams, P. M. Davis, N. Wyzga, T. Lerer, A. M. GriffithsOsteopenia in Children With Inflammatory Bowel Disease Is Due to PersistentDecrease in Bone Formation. Poster at the Annual meeting of the AmericanSociety for Bone & Mineral Research, Seattle WA, October 2004.

• F. A. Sylvester, N. Wyzga, S. Varghese, E. Canalis Interferon-γ Inhibits SmadSignaling and Osteoblast Differentiation. Poster at the Annual meeting of theAmerican Society for Bone & Mineral Research, Seattle WA, October 2004.

• Samuel Varghese, Nancy Wyzga, Francisco A. Sylvester Activated T Cell FactorsInhibit Bone Formation In Vitro. Poster at the Annual Meeting of the AmericanSociety of Bone & Mineral Research Minneapolis, September 2003 NancyWyzga, Jeffrey S. Hyams, Trudy Lerer, Patricia M. Davis, Anne M. Griffiths,Samuel Varghese, Francisco A Sylvester. A Role for Activated T Cells inOsteoporosis in Crohn Disease. Poster at the Annual Meeting of the AmericanGastroenterological Association, May 2003, Orlando, FL.

• Sylvester FA, Hyams JS, Greenstein R, Abbott MA, Feigenbaum A. ExtremeAminotransferase Elevation Following the Onset of Treatment in Female Carriersof Ornithine Transcarbamylase Deficiency. Poster at the Annual Meeting of theAmerican Gastroenterological Association, May 2003, Orlando, FL.

• Nancy Wyzga, Samuel Varghese, Francisco Sylvester. The effect of T cells onosteoclastogenesis depends on how they become activated. Poster at theAnnual Meeting of the American Society of Bone & Mineral Research SanAntonio, September 2002.

• FA Sylvester, JS Hyams, C Justinich, D Zeiter, M Zachos, AM Griffiths. Boneturnover is enhanced following treatment of Crohn’s disease: a prospective studyamong newly diagnosed patients. Poster at the Annual Meeting of the NorthAmerican Society for Pediatric Gastroenterology, Hepatology, and Nutrition(NASPGHAN) in Orlando, FL, October 2001.

• Varghese S, Wyzga N, Griffiths AM, Sylvester FA. Direct effects of serum fromchildren with Crohn's Disease on bone formation. Poster presentation at theAnnual Meeting of the American Gastroenterological Association, Atlanta, GA,May 2001.

• F.A. Sylvester, N. Wyzga, J.S. Hyams, G.A. Gronowicz. Does IL-6 contribute toosteopenia in children with Crohn’s disease? Presented at the Digestive DiseaseWeek, New Orleans, LA, May 1998.

• M.A. Marcon, F.A. Sylvester, B. Schukett, E. Cutz, P.R. Durie. Natural history offibrosing pancreatitis in children. Annual Meeting of The North American SocietyFor Pediatric Gastroenterology And Nutrition. Toronto, Ontario, October 1997.

• Sajjan, U.S., Sylvester, F.A., Forstner, J.F. Cable-Piliated B. cepacia bind toepithelial cytokeratins. Tenth Annual North American CF Conference, Orlando,Florida, October 24-27, 1996.

Florida, October 24-27, 1996.• F. A. Sylvester, B. Shuckett, E. Cutz, P. R. Durie, M. A. Marcon. Fibrosing

pancreatitis presenting with common bile duct stricture and progressing topancreatic exocrine failure. Annual Meeting of The North American Society ForPediatric Gastroenterology And Nutrition. Denver, Colorado, October 3-5, 1996.

• F. A. Sylvester, A. Ricci Jr., C. J. Justinich, J. S. Hyams. Intestinal inflammation invipoma-associated diarrhea. Annual Meeting of The North American Society ForPediatric Gastroenterology And Nutrition. Denver, Colorado, October 3-5, 1996.

• Sylvester FA, Forstner JF. Evidence for at least Two Receptor-Adhesin Systems ina Cable Pili Negative Clinical Isolate of Burkholderia cepacia. Poster presentationat the 95th General Meeting of the American Society for Microbiology,Washington DC, May 1995.

• Sylvester FA, Gold B, Lastovica A, Forstner JF: Evidence for the binding ofCampylobacter upsaliensis to lipid receptors via an exoenzyme S-like adhesin.Poster presentation at the Fourth Joint NASPGAN-ESPGAN Meeting, Houston,Texas, October 10-12, 1994.

• Sylvester FA, Sherman P, Forstner JF: Adherence to lipids and intestinal mucin bya newly recognized pathogen Campylobacter upsaliensis. Presented at the theSixth Annual Pediatric Residents and Fellows Research Symposium, Universityof Manitoba, Winnipeg, Manitoba, May 19, 1994.

• Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P: Pentasa in active smallintestinal Crohn's disease; a double-blind placebo-controlled crossover trial inchildren. Meeting of the American Gastroenterological Association, PosterPresentation, May 1992. Gastroenterology 1992: 102: A 632f.

Other presentations

• Sylvester FA, Sajjan U, Forstner JF: Globotriosylceramide (Gb3) is the major lipidreceptor for Burkholderia (Pseudomonas) cepacia. Winner of the 1994 TisdallAward Competition, The Hospital for Sick Children, Department of Pediatrics,May, 1994.

• Sylvester FA, Gold B, Lastovica A, Forstner J, Sherman P: "Campylobacterupsaliensis" binds to specific lipid receptors in vitro. Canadian Association ofGastroenterology, 2nd Annual Postgraduate Course in Gastroenterology, March1993. Oral Presentation.

Teaching Activities

Director of the Pediatric Gastroenterology Fellowship program University of NorthCarolina at Chapel Hill 7/1/2016 - PresentDirector of the Pediatric Gastroenterology Fellowship program at the University ofConnecticut School of Medicine 7/1/2010 – 9/30/2014.

Lectures to medical students

• The Disorders of Metabolism section of the Mechanisms of Disease Course (2nd

year medical students): The Gut Microbiome; Inflammatory Bowel Disease(yearly 2009 –2014).

• Lectures to medical students (University of Connecticut School of Medicine)Advanced Microbiology: The Gut Microbiome in IBD – 2014.

Grand Rounds outside UNC

• Egleston Pediatric Grand Rounds: The New Biology of the Growing Skeleton.Emory University, December 2016.

• Why doesn't everyone develop IBD? NYU Pediatric Grand Rounds, New York, NY,May 2014.

• Grand Rounds Children’s Hospital Boston, “Bone Health in Inflammatory BowelDiseases,” October 7, 2009.

• Pediatric Grand Rounds – Vitamin D: Beyond Bones - Connecticut Children’sMedical Center, March 2009.

• Visiting Professor – University of California San Francisco – October 21-23, 2008.Gave adult and pediatric Grand Rounds, and a Research Seminar on “SkeletalHealth in Inflammatory Bowel Disease, Clinical Features and Mechanisms”.

• Pediatric Grand Rounds: “Chronic illness in children and bone health” Mount SinaiMedical Center, September 2007.

• Adult GI Grand Rounds: “IBD and Bone Loss” Mount Sinai Medical Center,September 2007.

• Pediatric Grand Rounds: “Pediatric chronic disease and the skeleton: the exampleof Crohn disease” Riley Hospital for Children, Indianapolis, Indiana 2007.

• Grand Rounds “Bone and Pediatric Disease” Weill Cornell Medical College – NewYork Presbyterian Hospital, February 27, 2007.

• Pediatric GI Grand Rounds, Columbia Presbyterian Hospital, June 2006.

• Celiac Disease. Pediatric Grand Rounds. Saint Francis Hospital & Medical Center,Hartford, CT, February 2004.

• Make no bones about it, osteoporosis is a pediatric disease! Grand Rounds,Connecticut Children's Medical Center, Hartford, CT, February 2003.

• An update on gastroesophageal reflux in children. Grand Rounds, Saint FrancisHospital, Hartford, Connecticut. March, 1999.

• The brain-gut axis. Neurology Grand Rounds. Connecticut Children’s MedicalCenter, Hartford Hospital. December 4, 1997.

• Helicobacter pylori in children. Grand Rounds. Connecticut Children’s MedicalCenter, Hartford, Connecticut. November 11, 1997.

• Inflammatory bowel diseases in children. Grand Rounds, Saint Francis Hospital,Hartford, Connecticut. December, 1996.

• Helicobacter pylori in children. Grand Rounds, Saint Francis Hospital, Hartford,Connecticut. October 18, 1996.

• Molecular "lollipops": membrane glycolipids as receptors for microorganisms.Grand Rounds: University of Calgary, Department of Pediatrics. June 15, 1994.

Presentations outside UNC

• Clinical features of pediatric IBD; Vitamin D: Classical and Anti-inflammatory Roles;Pathophysiology of IBD; Role of the Gut Microbiome in Health and Disease;Celiac disease @ IV International Course in Pediatric Gastroenterology,Hepatology and Nutrition - Peruvian Pediatric Society, July 2014.

• Vitamin D and Pediatric IBD. 2nd Annual Pediatric IBD Research Day –Presbyterian Morgan Stanley Children's Hospital/Columbia University Medical

Presbyterian Morgan Stanley Children's Hospital/Columbia University MedicalCenter, June 2014.

• Research Seminar, "Osteoprotegerin: from bone to gut and back", Michigan StateUniversity, East Lansing, MI February 2013.

• Research Seminar, “Crohn disease: from the intestine to the skeleton and back”,Yale Center for XLH, and our Yale Core Center for Musculoskeletal Disorders,New Haven, CT November 2011.

• Invited faculty, Yale CME: Crohn’s Disease: Understanding the Cause and theTreatment – “Diagnosis, Prevention and Management of Bone Disease inCrohn’s Disease” – April 17, 2009.

• Immunology Seminar Series, University of Connecticut Health Center,“Osteoprotegerin: from bone to gut and back”, February 26, 2009.

• Visiting Professor, Cincinnati Children’s Hospital (“Bone Health in Children withChronic Diseases”), January 11-12, 2008.

• Research seminar “Mechanisms of bone loss in IBD” and journal club“RANKL/OPG in IBD), The Hospital for Sick Children, Toronto, CanadaNovember 8-9, 2005.

• Crohn Disease, Bone Loss and T Cells. National Institutes of Health, Meeting ofthe Centers for Interdisciplinary Research in Women's Health, June 2003.

• Osteoporosis, Immune System Against Bone? Research Seminar, Division ofPediatric Gastroenterology, Johns Hopkins University, December 2002.

• Bone in Pediatric Health and Illness. 5th Advances in Pediatric Nutrition. Sponsoredby Johns Hopkins Children’s Nutrition Center and the Johns Hopkins University.School of Medicine Division of Pediatric Gastroenterology and Nutrition,Department of Pediatrics, June 2002.

• Crohn’s disease and bone loss in children: basic pathogenic mechanisms.Research seminar, The Hospital for Sick Children, University of Toronto, Toronto,Ontario, Canada. November 3, 1999.

• Advances in Helicobacter pylori. 16th Annual Pediatric Alumni Day, Children’sMedical Center of Brooklyn. June 25, 1998.

• Approaches to the study of two receptor-adhesin systems. Research Seminar:University of Calgary. June 16, 1994.

• What is new in Burkholderia cepacia research? Talk at the Annual Retreat of TheResearch Institute, The Hospital for Sick Children, Toronto. December, 1994.

Resident Advisor

• Luis Sifuentes, MD – Pediatric Gastroenterology Fellow 2012 – 2015 – AssistantProfessor – UT Southwestern Medical Center, Dallas, TX.

• Johanna Palmadottir, MD – Pediatric Gastroenterology Fellow 2011 – 2014 –University of Connecticut School of Medicine – Assistant Professor at MedicalUniversity of South Carolina.

• Vi Goh, MD – Pediatric Gastroenterology Fellow 2009 – 2012 – Medical College ofWisconsin, Milwaukee, WI. Assistant Professor at Boston University School ofMedicine.

Grants

Active 1R01HD075929 (Gupta) 12/1/2014 – 4/30/2019 NIH/Weill Cornell Medical College $159,196Sex Differences in Statural Growth Impairment in Pediatric Crohn's DiseaseTo test if the inflammation characteristic of Crohn's disease has greater adverse effectson endocrine growth regulators (IGF-1 levels, sex hormone levels, and gonadotropinlevels) in males and that these greater negative inflammatory effects help explain theincreased susceptibility to growth impairment in males.Role: Site PI, 0% FTE 1U01DK095745-01 (Hyams) 05/01/12 – 10/30/2014NIH/NIDDK $10,433,231 Predicting Response to Standard Pediatric Colitis Therapy: The PROTECT studyThe PROTECT Study will, for the first time, describe the course of children newlydiagnosed with ulcerative colitis treated with standardized therapy that has beendevised to minimize exposure to more toxic drugs. By concomitantly obtainingbiospecimens at diagnosis and during the first year following therapy PROTECT willfacilitate the understanding of inter-patient variability in response to therapy and provideinsights into the pathways that sustain colonic inflammation. This effort will not onlyimprove the health of children newly diagnosed with ulcerative colitis, but will alsolessen the likelihood of medication toxicity and the need for colectomy.Role: Co-Investigator, 5% FTE CompletedNo Number (Sylvester) 3/1/13-2/28/16 Crohn’s & Colitis Foundation of America $80,000PRO-KIIDS This award provides leadership, infrastructure and administrative support for multi-institutional collaborative research involving children with IBD.Role: Principal Investigator, 10% FTE 5U01AI095776 (Lewinsohn) July 1, 2013 – 10/30/14NIH $174,253Colonic γδ T cells in pediatric Crohn diseaseThe goals of this proposal are to characterize the transcriptome of colonic γδ T cells inpediatric Crohn disease and their cytokine productionRole: Site Principal Investigator, 5% FTE Institutional Support for Research Initiatives (Sylvester) 10/1/13 – 9/30/14Connecticut Children’s Medical Center $377,697Collaborations between UCHC-Dr. Anthony Vella and CCMC Dr. FranciscoSylvesterIn this project we are investigating immune mechanisms of pediatric inflammatory boweldisease. This human immunology project is allowing us the opportunity to contrastvarious aspects of inflammation in colon and the responses of lamina propria cells. Wehope to develop biomarkers and gain new insight into the disease process in pediatricpatient.Role: Principal Investigator, 27% FTE 1R01HD067174-01A1 (Hommel/Sylvester) 8/1/11 – 7/31/14NIH/NICHD/ Cincinnati Children’s Hospital $171,486Telehealth Enhancement of Adherence to Medication in Pediatric IBD (TEAMStudy)The primary goal of this study is to test the efficacy of a telehealth behavioral treatmenton medication adherence, disease severity, health-related quality of life, and health careutilization in children and adolescents with IBD compared to an education only

utilization in children and adolescents with IBD compared to an education onlyintervention.Role: Site Principal Investigator, 5% FTE Incentive Grant 178421 (Sylvester) 10/1/2009 – 9/30/2012Friends of Connecticut Children’s Medical Center $25,000Osteoprotegerin StudyThe major goals of this project are to support pilot laboratory projects pertaining to bonehealth and inflammatory bowel diseases in children. In particular our focus is on the roleof mucosal Osteoprotegerin in prolonging the lifespan of inflammatory cells in theintestine in patients with IBD.Role: Principal Investigator, 5% FTE CICATS Pilot Grant (Sylvester and Vella) 7/1/11-6/30/12 $50,000Revealing a functional role for intestinal T cells in inflammatory bowel diseaseThis multiple Principal Investigator pilot grant will investigate the role of T cells usinghuman biopsy specimens from pediatric IBD patients. Our team will use a basictranslational approach to bridge the clinical symptoms associated with disease to basicimmunological mechanism. We propose that T helper cell imbalance in the colon fuelsdisease causing cytokine networks and our goal is uncover this process using flowcytometry and in situ analysis.Role: Principal Investigator, Multiple-PI award, 10% FTE1U34DK090804-01 (Hyams, PI) 09/30/10-04/30/12 NIH/NIDDK 05/01/11 – 4/30/12 $424,535Predicting Response to Standard Pediatric Colitis Therapy: The PROTECT studyThe U34 project will conduct the planning activities to initiate a prospective clinical trialof standardized medical therapy in pediatric Ulcerative Colitis. Overlap: This is theplanning grant for the current U01 proposal.Role: Co-Investigator, 5% FTE Incentive Grant 179599 (Sylvester) 4/1/2009 – 6/30/2011University of Connecticut Health Center & Regional Campus IncentiveGrant $2,500Osteoblasts: Immune Responses in Pediatric Inflammatory Bowel DiseaseThe major goals of this project are to characterize the immunophenotypic features ofcirculating osteoblasts obtained from children with untreated IBD.Role: Principal Investigator, 0% FTE DK-066303 (Sylvester) 8/1/04 – 7/31/09National Institutes of Health $200,000/yearMechanisms of Bone Loss in Pediatric Crohn DiseaseGoals: 1. To examine calcium kinetics in children with Crohn disease. 2. To examine theeffects of INF-γ on BMP-2 signaling.Role: Principal Investigator, 20% FTE (Sylvester) 1/1/04-12/30/08The Patrick and Catherine Weldon Donaghue Medical Research FoundationUnderstanding bone loss in children with chronic gastrointestinal disease$100,000/yearExamines the pathophysiology of bone loss in children with chronic digestive diseases.Role: Principal Investigator, 50% FTE (Sylvester) 7/1/02-6/30/04Crohn’s & Colitis Foundation of America. $50,000/yearPathophysiology of Bone loss in IL-10 knockout mice with colitisStudies the bone phenotype of IL-10 knockout mice.

Studies the bone phenotype of IL-10 knockout mice.Role: Principal Investigator, 20% FTE 5K12HD01409-01 (K-12 career development award). 5/15/2001-5/15/2004NIH/University of Connecticut Center for Interdisciplinary Research in Women’s Health.$100,000/yearMechanisms of osteoporosis in Crohn’s DiseaseGoal of project is to examine the effect of cytokines on signaling pathways of boneanabolic factors.Role: Scholar 75% FTE (Sylvester) 6/1/2001-5/13/2002 $60,000Connecticut Children’s Medical Center Research and Education Endowment.Effects of Crohn’s disease on osteoblast differentiationExamined the effect of serum from newly diagnosed children with Crohn’s disease onthe differentiation of osteoblasts.Role: Principal Investigator 10% FTE (Sylvester) 1/1/00-12/31/02 $50,000/yearThe Patrick and Catherine Weldon Donaghue Medical Research Foundation.Crohn’s Disease and OsteopeniaExamined the role of IL-6 on the effects of serum from children with Crohn disease on abone organ culture model.Role: Principal Investigator 10% FTE (Sylvester) 1/1/98-12/31/2000Crohn’s & Colitis Foundation of America $80,000/yearCrohn’s disease and osteopenia in children: basic pathogenic mechanismsProspective study of bone mineral density in children with inflammatory bowel diseasefrom the time of diagnosis and the role of circulating factors present in children withCrohn’s disease on bone turnover in vitro.Role: Principal Investigator 10% FTE (Sylvester) 1997Hartford Foundation for Public GivingChemokine expression in Helicobacter pylori induced gastritis in children.Comparison with H. pylori gastritis in adults $52,000Studied the gastric inflammatory response to H. pylori infection in children and adults,specifically at the local expression of cell-traffic signals.Role: Principal Investigator 10% FTE Professional Service Connecticut Children’s Medical Center (CCMC), Hartford, CT

• Research Council 2009-2014

• Institutional Review Board Committee February 1990-2014

• Chair of CCMC Investigator Track Task Force 2010

• Faculty Practice Plan Operations Committee, 2005-2009

• Faculty Practice Plan Research Task Force, Leader 2005-2008

• CCMC Clinical Information System Steering Committee, 2005-2008

• NICU/PICU/Well baby Redesign Task Force (Chair) 2003–2004

• Pharmacy & Therapeutics Committee February 1996–2001

• Research Director Search Committee 1999–10/2000

• Mini-internship Program Invited Faculty (6 separate programs) 1998-2000

• Mini-internship Program Invited Faculty (6 separate programs) 1998-2000

• Research Steering Committee October 1996–October 2000

• Faculty Mentoring Task Force June - July 1999

North American Society for Pediatric Gastroenterology, Hepatology and Nutrition(NASPGHAN)

• Inflammatory Bowel Diseases Committee 2008 – 2011

• Awards Committee 2010

• Liaison Committee 2005 – 2008

• Nutrition Committee. 2004 – 2008

• Internet Committee. Duties included serving as Secretary of the committee andhelping with the redesign of the NASPGHAN web site. 2001 – 2003

Crohn’s & Colitis Foundation of America

• Board of Trustees – October 2009-2012; November 2012 – 03/03/2016

• Chair – Pediatric Growth and Skeletal Health in Inflammatory Bowel DiseasesWorkshop, New York City, November 11 – 12, 2011

• Crohn’s & Colitis Foundation of America, Chair – Pediatric Affairs Committee 11/05– 10/08

• Chair – Task force on Research Priorities in Bone Health & Growth in Children withInflammatory Bowel Disease 2004 – 2005

Peer Reviewer (Journals & Grants)Editorial Board

• Journal of Pediatric Gastroenterology and Nutrition (2014 - present)

• Inflammatory Bowel Diseases (Associate Editor 2008-2013; Executive Editor 2013– November 2016)

Peer reviewer

• American Journal of Gastroenterology (2007, 2008, 2009, 2010)

• Clinical and Experimental Immunology (2015)

• Clinical Gastroenterology and Hepatology (2008, 2012)

• Digestive Diseases and Sciences (2013, 2014)

• Gastroenterology (2008, 2010, 2011, 2012)

• Inflammatory Bowel Diseases (2006 – 2015)

• Journal of Pediatric Gastroenterology and Nutrition (2005 – 2015)

• Journal of Crohn’s and Colitis (2015)

Grants

• Department of Defense Peer Review Research Program (2006, 2008)

• Crohn’s and Colitis Foundation of America (since 2009, yearly)

• Crohn’s & Colitis Foundation of Canada (2009)

• NIH Loan Repayment Program (since 2004, yearly)

Abstracts• Abstract Review Committee: Advances in Inflammatory Bowel Diseases: Crohn’s &

• Abstract Review Committee: Advances in Inflammatory Bowel Diseases: Crohn’s &Colitis Foundation’s Clinical & Research Conference (2015, 2016)

Research StatementMy laboratory conducts human translational studies grounded on clinical observations inchildren with inflammatory bowel diseases. We formulate hypotheses based on thesefindings, which we test in mouse models and cell culture systems. Areas of interestinclude mucosal immunology, vitamin D and bone metabolism in pediatric IBD. We aimto uncover pathogenic pathways that can be targeted for new therapies. Since my arrival to UNC at the end of October 2014, we are actively developing 3projects in my laboratory: Osteoprotegerin (OPG) as part of the innate immune response to infection in the colonicepitheliumOPG is best known as an inhibitor of osteoclast formation and development. We havediscovered that the colonic epithelium exhibits robust expression of OPG. OPG issecreted by colonocytes in response to infection and inflammatory cytokines. We haveshown that OPG binds to a variety of organisms, from bacteria to parasite eggs. Wehypothesize that OPG adheres to carbohydrates expressed on the surface of colonicmicrobes with its heparin-binding domain. We postulate that OPG is an innate opsoninthat facilitates phagocytosis by mucosal macrophages. Therefore, we believe that OPGhelps to clear microbes that penetrate the colonic lamina propria. We are testing ourhypothesis in the laboratory using primary macrophages and macrophage cell lines. Weare planning to collaborate with the group of Dr. Susan Henning to leverage colonicorganoid generated in their laboratories to characterize the role of OPG in epithelial-microbial interactions. We have observed that colonic expression of OPG tracks with disease severity ofulcerative colitis. We also have demonstrated that mice that lack OPG are resistant toexperimental colitis. Consequently, blocking OPG activity in the lumen of the colon maybecome a new therapeutic strategy to treat colitis in humans. We plan to test thispossibility in laboratory mice first. Our animal protocol was just approved to pursuethese studies. Vitamin D as adjuvant therapy for Crohn diseaseCrohn disease is characterized by chronic transmural inflammation of any portion of thegastrointestinal tract. The onset of Crohn disease is triggered by environmental factorsthat affect the enteric microbiota, leading to intestinal inflammation in geneticallypredisposed hosts. A number of genes that confer susceptibility to Crohn diseaseencode for proteins that are important in the detection, recognition and processing ofmicrobes. Therefore, Crohn disease can be viewed as an immune deficiencycharacterized by defective clearance of microbes by phagocytic cells. In addition to its well-known actions in bone, vitamin D in macrophages stimulates thesynthesis of anti-microbial peptides and induces changes in lysosomal vesicles to makethem more hostile against ingested bacteria. We therefore hypothesize that vitamin Dsupplementation in patients with Crohn disease improves the killing ability ofmacrophages. To begin to examine these putative effects, we have recently receivedIRB approval to collect blood samples in children with Crohn disease in stable clinicalremission before a scheduled infusion of infliximab, and then 6 – 8 weeks after oralvitamin D supplementation. We will examine phagocytic activity and microbial lyticactivity in the lab. If results are promising, our data would set the stage for a clinical trial,to evaluate vitamin D as adjuvant therapy for patients with Crohn disease. The effects of the Crohn disease microbiome on skeletal developmentTogether with Dr. Ian Carroll, Assistant Professor of Medicine and an expert in the

Together with Dr. Ian Carroll, Assistant Professor of Medicine and an expert in theenteric microbiome, we have recently applied for an NC TraCS pilot grant to evaluatehow the Crohn disease microbiome affects skeletal development. Crohn disease can affect normal skeletal development and linear growth in children.Children with Crohn disease can have significant deficits in bone mineral density,alterations in bone geometry and growth stunting at diagnosis. The enteric microbiota inCrohn disease is characterized by blooming of pathogenic species and reduction inoverall microbial diversity, even at the time of diagnosis. There are reports thatprobiotics and normal mouse enteric flora affects bone density and bone architecture inmice. We plan to reconstitute the enteric microbiota of gnotobiotic mice with stool collectedfrom newly diagnosed, untreated children with Crohn disease and healthy controls. Wewill evaluate the skeletal phenotype of these mice at defined time points, until theirlinear growth ceases. We will leverage our data to apply for federal sources of funding. Teaching StatementI strongly believe in organizing medical educational content in practical form that can beeasily incorporated in the knowledge base of learners, and used to the benefit of ourpatients. I enjoy guiding students, residents and fellows in distilling the physiologicaldisturbances that underlie clinical findings or abnormal laboratory values, to be able tooffer our patients medical care that is grounded on sound reasoning and best availableevidence. I believe in a positive educational environment, where learners enjoy theprocess of discovery and become committed to learning throughout their professionallife because it is fun! I hope to be able to inspire learners of all levels to follow ourcareer path in pediatric gastroenterology, and motivate them to become physician-investigators. Service and Engagement StatementAs Division Head of Pediatric Gastroenterology, I am committed to leading the Divisionin providing the best possible care to our patients, to being available to the communityof health care providers to offer prompt, expert consultation on their patients, and tofostering the professional development of the members of the Division. Their success ismy success. I am also committed to advancing the care of patients with inflammatory bowel disease.My service at the Crohn’s and Colitis Foundation of America as a Board of Trusteesmember, as a member of the North Carolina Triangle Board, and as a member of theNational Scientific Advisory Committee and Chair of PROKIIDS are the vehicles bywhich I have advocated for children with IBD and their families. Lastly, I am motivated to give back to my home country of Peru, by housing qualifiedvisiting rotators from my medical school and other institutions, and by visiting toparticipate in continuing medical education events.25